Placenta accreta spectrum

Prytime Medical Announces Appointment of Robert A. Cohen, M.D., to its Clinical Advisory Board

Retrieved on: 
Wednesday, November 22, 2023
Placenta, Research, SAN, Gynaecology, Medical director, Bleeding, Placenta accreta spectrum, Patient, Obstetrics, REBOA, University, Mother, Medical City Dallas Hospital, Medical City, Medical college, PAS, Physician, Medical College of Wisconsin, Medical device

SAN ANTONIO, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Prytime Medical Devices Inc, The REBOA Company™, the leading innovator and global provider of lifesaving REBOA products announced that board-certified obstetrician-gynecologist Robert A. Cohen, M.D., has joined the company's Clinical Advisory Board effective immediately.

Key Points: 
  • Dr. Cohen is the Medical Director of the Placenta Accreta Program at Medical City Dallas and is also a member of the AOA Honor Medical Society.
  • He is invested in research and recently published a paper on improved placement location of REBOA catheter in pelvic hemorrhage.
  • "Dr. Cohen joins the Prytime team as a highly recognized leader in the industry and brings first-hand clinical experience that transcends obstetrics," said David Spencer, Prytime Medical Devices, Inc.'s CEO.
  • Dr. Cohen received his medical degree from Medical College of Wisconsin and completed residency at the University of Texas Southwestern Medical Center.